| Code | CSB-RA004966MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Crefmirlimab, designed to target CD8A (CD8 alpha), a transmembrane glycoprotein that forms part of the CD8 co-receptor complex on cytotoxic T lymphocytes and natural killer cells. CD8A plays a critical role in T cell receptor signal transduction by binding to MHC class I molecules, thereby facilitating antigen recognition and T cell-mediated immune responses. This molecule is essential for the development, activation, and effector functions of CD8+ T cells, which are crucial for antiviral immunity and tumor surveillance. Dysregulation of CD8+ T cell function is implicated in various pathological conditions, including cancer immune evasion, autoimmune disorders, and chronic viral infections.
Crefmirlimab represents a therapeutic antibody developed for oncology applications, particularly targeting the CD8+ T cell compartment to modulate anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating CD8+ T cell biology, immune checkpoint mechanisms, tumor microenvironment interactions, and immunotherapeutic strategies. It enables studies exploring T cell exhaustion, immune cell trafficking, and cellular immunotherapy approaches in preclinical models.
There are currently no reviews for this product.